Impact of Endothelial Progenitor Cells on Tumor Angiogenesis and Outcome of Antiangiogenic Therapy: New Perspectives on an Ongoing Controversy

  • Robert S. Kerbel
  • Francesco Bertolini
  • Yuval Shaked
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Tumor angiogenesis is driven not only by proliferation of differentiated endothelial cells in sprouting capillaries from pre-existing mature vessels, but also by mobilization of bone marrow derived circulating endothelial progenitor cells (EPCs). The latter are thought to home to the tumor site and incorporate into the lumen of newly growing blood vessels. Over the past several years, a growing number of reports have challenged the hypothesis concerning the involvement of EPCs in tumor angiogenesis, and instead suggest that such cells only have a minor role, if any at all, in the formation of tumor-associated blood vessels. Consequently, these studies implicate EPCs as a minor or negligible target for cancer therapy. In this review, we discuss the arguments for and against a significant role of EPCs in tumor angiogenesis and growth, and as possible surrogate markers of angiogenesis as well as valuable therapeutic targets.


Tumor Angiogenesis Maximum Tolerate Dose Tumor Blood Vessel Antiangiogenic Drug Mature Endothelial Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Asahara T, Murohara T, Sullivan A et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967.PubMedCrossRefGoogle Scholar
  2. Beerepoot LV, Radema SA, Witteveen EO et al (2006) Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491–1498.PubMedCrossRefGoogle Scholar
  3. Bender JL, Adamson PC, Reid JM et al (2008) Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 26:399–405.CrossRefGoogle Scholar
  4. Bertolini F, Paul S, Mancuso P et al (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342–4346.PubMedGoogle Scholar
  5. Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: from promiscuity to surrogate marker and target identification. Nature Rev Cancer 6:835–845.CrossRefGoogle Scholar
  6. Brown M et al (2010), J Clin Investig (in press).Google Scholar
  7. Buckstein R, Kerbel RS, Shaked Y et al (2006) High-Dose celecoxib and metronomic “low-dose” cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin’s lymphoma. Clin Cancer Res 12:5190–5198.PubMedCrossRefGoogle Scholar
  8. Calleri A, Bono A, Bagnardi V et al (2009) Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clin Cancer Res 15:7652–7657.PubMedCrossRefGoogle Scholar
  9. Case J, Mead LE, Bessler WK et al (2007) Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 35:1109–1118.PubMedCrossRefGoogle Scholar
  10. Coffelt SB, Hughes R, Lewis CE (2009) Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796:11–18.PubMedGoogle Scholar
  11. Cubbon RM, Kahn MB, Wheatcroft SB (2009) Effects of insulin resistance on endothelial progenitor cells and vascular repair. Clin Sci (Lond)117:173–190.CrossRefGoogle Scholar
  12. Dellapasqua S, Bertolini F, Bagnardi V et al (2008) Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer. J Clin Oncol 26(30):4899-4905.PubMedCrossRefGoogle Scholar
  13. De Palma M, Naldini L (2006) Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 1766:159–166.PubMedGoogle Scholar
  14. De Palma M, Venneri MA, Galli R et al (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8:211–226.PubMedCrossRefGoogle Scholar
  15. Distler JH, Beyer C, Schett G, Luscher TF, Gay S, Distler O (2009) Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases. Arthritis Rheum 60:3168–3179.PubMedCrossRefGoogle Scholar
  16. Duda DG, Cohen KS, di Tomaso E et al (2006) Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 24:1449–1453.PubMedCrossRefGoogle Scholar
  17. Elshal MF, Khan SS, Takahashi Y, Solomon MA, McCoy JPJr (2005) CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood. Blood 106:2923–2924.PubMedCrossRefGoogle Scholar
  18. Farace F, Massard C, Borghi E, Bidart JM, Soria JC (2007) Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. Ann Oncol 18:1421–1422.PubMedCrossRefGoogle Scholar
  19. Gammill HS, Lin C, Hubel CA (2007) Endothelial progenitor cells and preeclampsia. Front Biosci 12:2383–2394.PubMedCrossRefGoogle Scholar
  20. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319:195–198.PubMedCrossRefGoogle Scholar
  21. Grunewald M, Avraham I, Dor Y et al (2006) VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124:175–189.PubMedCrossRefGoogle Scholar
  22. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045–1047.PubMedCrossRefGoogle Scholar
  23. Horrevoets AJ (2009) Angiogenic monocytes: another colorful blow to endothelial progenitors. Am J Pathol 174:1594–1596.PubMedCrossRefGoogle Scholar
  24. Jin DK, Shido K, Kopp HG et al (2006) Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12:557–567.PubMedCrossRefGoogle Scholar
  25. Kaplan RN, Psaila B, Lyden D (2007) Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med 13:72–81.PubMedCrossRefGoogle Scholar
  26. Kerbel RS (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 13:31–36.PubMedCrossRefGoogle Scholar
  27. Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312:1171–1175.PubMedCrossRefGoogle Scholar
  28. Kerbel RS, Benezra R, Lyden DC et al (2008) Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc Natl Acad Sci U S A 105:E54.PubMedCrossRefGoogle Scholar
  29. Kim I, Yilmaz OH, Morrison SJ (2005) CD144 (VE-cadherin) is transiently expressed by fetal liver hematopoietic stem cells. Blood 106:903–905.PubMedCrossRefGoogle Scholar
  30. Kim JJ, Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5:516–525.PubMedCrossRefGoogle Scholar
  31. Kim SJ, Kim JS, Papadopoulos J et al (2009) Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am J Pathol 174:1972–1980.PubMedCrossRefGoogle Scholar
  32. Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15–R24.PubMedCrossRefGoogle Scholar
  33. Lawler J (2002) Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1–12.PubMedCrossRefGoogle Scholar
  34. Li H, Gerald WL, Benezra R (2004)Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res 64:6137–6143.PubMedCrossRefGoogle Scholar
  35. Lyden D, Hattori K, Dias S et al (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201.PubMedCrossRefGoogle Scholar
  36. Lyden D, Young AZ, Zagzag D et al (1999) Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401:670–677.PubMedCrossRefGoogle Scholar
  37. Machein MR, Renninger S, Lima-Hahn E, Plate KH (2003) Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 13:582–597.PubMedCrossRefGoogle Scholar
  38. Madlambayan GJ, Butler JM, Hosaka K et al (2009) Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood 114:4310–4319.PubMedCrossRefGoogle Scholar
  39. Mancuso P, Antoniotti P, Quarna J et al (2009) Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 15:267–273.PubMedCrossRefGoogle Scholar
  40. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658–3661.PubMedCrossRefGoogle Scholar
  41. Mancuso P, Colleoni M, Calleri A et al (2006) Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108:452–459.PubMedCrossRefGoogle Scholar
  42. Martin-Padura I, Bertolini F (2008) The circulating endothelial cell in cancer: towards marker and target identification. Curr Pharm Des 14:3780–3789.PubMedCrossRefGoogle Scholar
  43. Nathan PD, Judson I, Padhani A et al (2008) A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 26(15S, Abstract No. 3550), —20 May 2008.Google Scholar
  44. Peichev M, Naiyer AJ, Pereira D et al (2000) Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95:952–958.PubMedGoogle Scholar
  45. Peters BA, Diaz LA, Polyak K et al (2005) Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11:261–262.PubMedCrossRefGoogle Scholar
  46. Pitchford SC, Furze RC, Jones CP, Wengner AM, Rankin SM (2009) Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell 4:62–72.PubMedCrossRefGoogle Scholar
  47. Prewett M, Huber J, Li Y et al (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209–5218.PubMedGoogle Scholar
  48. Purhonen S, Palm J, Rossi D et al (2008) Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A 105:6620–6625.PubMedCrossRefGoogle Scholar
  49. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826–835.PubMedCrossRefGoogle Scholar
  50. Rohan RM, Fernandez A, Udagawa T, Yuan J, D’Amato RJ (2000) Genetic heterogeneity of angiogenesis in mice. FASEB J 14:871–876.PubMedGoogle Scholar
  51. Roodhart JM, Langenberg MH, Vermaat JS et al (2010) Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia 12:87–94.PubMedGoogle Scholar
  52. Ruzinova MB, Schoer RA, Gerald W et al (2003) Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 4:277–289.PubMedCrossRefGoogle Scholar
  53. Schneider M, Tjwa M, Carmeliet P (2005) A surrogate marker to monitor angiogenesis at last. Cancer Cell 7:3–4.PubMedCrossRefGoogle Scholar
  54. Shaked Y, Bertolini F, Emmenegger U, Lee CR, Kerbel RS. (2006a) On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent. J Clin Oncol 24:4040–4041.PubMedCrossRefGoogle Scholar
  55. Shaked Y, Bertolini F, Man S et al (2005a) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7:101–111.PubMedGoogle Scholar
  56. Shaked Y, Ciarrocchi A, Franco M et al (2006b) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785–1787.PubMedCrossRefGoogle Scholar
  57. Shaked Y, Emmenegger U, Francia G et al (2005b) Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 65:7045–7051.PubMedCrossRefGoogle Scholar
  58. Shaked Y, Emmengger U, Man S et al (2005c) The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106:3058–3061.PubMedCrossRefGoogle Scholar
  59. Shaked Y, Henke E, Roodhart JM et al (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14:263–273.PubMedCrossRefGoogle Scholar
  60. Shaked Y, Kerbel RS (2007) Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 67:7055–7058.PubMedCrossRefGoogle Scholar
  61. Shaked Y, Tang T, Woloszynek J et al (2009) Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res 69:7524–7528.PubMedCrossRefGoogle Scholar
  62. Shaked Y, Voest EE (2009) Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil? Biochim Biophys Acta 1796:1–4.PubMedGoogle Scholar
  63. Shojaei F, Wu X, Zhong C et al (2007) Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450:825–831.PubMedCrossRefGoogle Scholar
  64. Siemann DW, Chaplin DJ, Horsman MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer 100:2491–2499.PubMedCrossRefGoogle Scholar
  65. Solovey AN, Gui L, Chang L, Enenstein J, Browne PV, Hebbel RP (2001) Identification and functional assessment of endothelial P1H12. J Lab Clin Med 138:322–331.PubMedCrossRefGoogle Scholar
  66. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423–435.PubMedCrossRefGoogle Scholar
  67. Volpert OV, Pili R, Sikder HA et al (2002) Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2:473–483.PubMedCrossRefGoogle Scholar
  68. Werner N, Kosiol S, Schiegl T et al (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:999–1007.PubMedCrossRefGoogle Scholar
  69. Wickersheim A, Kerber M, de Miguel LS, Plate KH, Machein MR (2009) Endothelial progenitor cells do not contribute to tumor endothelium in primary and metastatic tumors. Int J Cancer 125:1771–1777.PubMedCrossRefGoogle Scholar
  70. Woodhouse EC, Chuaqui RF, Liotta LA (1997) General mechanisms of metastasis. Cancer 80:1529–1537.PubMedCrossRefGoogle Scholar
  71. Yap R, Veliceasa D, Emmenegger U et al (2005) Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 11:6678–6685.PubMedCrossRefGoogle Scholar
  72. Yoder MC, Mead LE, Prater D et al (2007) Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109:1801–1809.PubMedCrossRefGoogle Scholar
  73. Ziegelhoeffer T, Fernandez B, Kostin S et al (2004) Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 94:230–238.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Robert S. Kerbel
  • Francesco Bertolini
  • Yuval Shaked
    • 1
  1. 1.Department of Molecular Pharmacology, Rappaport Faculty of MedicineTechnion – Israel Institute of TechnologyHaifaIsrael

Personalised recommendations